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Background. Echinocandins are recommended as firstline therapy in patients with candidemia. However, there is debate on 
their efficacy in survival outcomes. The aim of this study is to evaluate whether the choice of initial antifungal therapy improves 
mortality in patients with candidemia in relation to the presence of septic shock.
Methods. Patients with candidemia hospitalized in internal medicine wards of 5 tertiary care centers were included in the 
study (December 2012–December 2014). Patient characteristics, therapeutic interventions, and outcome were reviewed. Propensity 
score (PS) was used as a covariate of the multivariate analysis to perform a stratified analysis according to PS quartiles and to match 
patients receiving “echinocandins” or “azoles.”
Results. Overall, 439 patients with candidemia were included in the study. A total of 172 (39.2%) patients had septic shock. 
Thirty-day mortality was significantly higher in patients with septic shock (45.3%) compared with those without septic shock 
(31.5%; P = .003). Among patients with septic shock, the use of echinocandins in the first 48 hours, compared with azoles, did not 
affect 30-day mortality in the PS-adjusted Cox regression analysis (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.37–1.59; 
P  =  .48), the PS-stratified analysis, or the logistic regression model in matched cohorts (adjusted HR, 0.92; 95% CI, 0.51–1.63; 
P = .77).
Conclusions. Echinocandin therapy seems not to improve the outcome of non–intensive care unit patients with septic shock due 
to candidemia. These findings support the urgent need of further studies in this patient population.
Keywords. candidemia; early antifungal therapy; echinocandins; septic shock.
In the last decade, Candida spp. has been recognized as the 
fourth most common cause of nosocomial bloodstream infec-
tion (BSI) [1, 2]. Despite the identification of risk factors for 
candidemia, the development of prediction rules for different 
patient populations, and advances in early diagnosis and treat-
ment, candidemia is still responsible for high costs, prolonged 
length of stay, and increased mortality rates [3–5]. Mortality is 
particularly high among patients with septic shock [6].
Current guidelines for the management of candidemia rec-
ommend an echinocandin as firstline therapy, confining the 
use of fluconazole as initial therapy only in patients who are 
not critically ill [7]. However, no study has evaluated the im-
pact of different antifungal agents on the outcome of patients 
with different clinical presentations, in particular among 
non-neutropenic patients with septic shock admitted to 
medical wards.
The aim of this study is to evaluate whether initial therapy 
with echinocandins improves mortality in patients with 
candidemia in relation to the presence of septic shock.
METHODS
Study Population and Study Design
This multicenter observational study was performed in 5 ter-
tiary care hospitals located in different regions in Italy:
 - Hospital 1: Policlinico Umberto I, “Sapienza” University, 
Rome (1100 beds)
 - Hospital 2: San Giovanni-Addolorata Hospital, Rome (700 
beds)
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 - Hospital 3: University Hospital of Trieste (840 beds)
 - Hospital 4: Azienda Ospedaliera Universitaria Pisana, Pisa 
(1000 beds)
 - Hospital 5: University Tor Vergata, Rome (460 beds)
The study included cases observed from December 2012 to 
December 2014 in the internal medicine wards (IMWs) of 
the participating sites. Hospitalized patients aged ≥18  years 
with a definite diagnosis of candidemia were included in the 
study. Candidemia was defined by at least 1 positive blood 
culture yielding Candida spp. in a patient with fever and/or 
other clinical signs of infection [8]. Exclusion criteria were age 
<18  years, neutropenia (defined as absolute neutrophil count 
<0.5 ×  109/L or expected to fall below 0.5 ×  109/L) and pres-
ence of hematological malignancy [9]. According to the study 
protocol, patients with candidemia hospitalized in nonmedical 
wards (surgery or intensive care unit [ICU]) were not included 
in the study. However, patients initially hospitalized in med-
ical wards who were transferred to the ICU after diagnosis 
of candidemia were included in the analysis. The local ethics 
committees approved the study in each center. According to 
local and national policies, informed consent was waived for 
this type of study.
Data Collection and Study Definitions
Demographic data, underlying diseases, reasons for hospital 
admission, and severity of illness of patients with definite di-
agnosis of candidemia were retrospectively reviewed on a 
standardized report form. The variables considered were age, 
sex, underlying diseases, weight of comorbidities assessed by 
the Charlson comorbidity index, presence of intravascular 
devices, such as central venous catheter (CVC) or peripherally 
inserted central catheter (PICC), administration of total par-
enteral nutrition (TPN) [10], surgery in the previous 30 days, 
and hospitalization in the previous 3 months. Previous antibi-
otic therapy, a recognized risk factor for candidemia [11], was 
defined as exposure to antibiotics for at least 48 hours in the 
30  days preceding candidemia. The administration of a con-
comitant antibiotic (defined as exposure to antibiotics within 
48 hours before diagnosis of candidemia) and immunosuppres-
sive therapy (defined as use of steroids [prednisolone >0.5 mg/
kg/d or equivalent for >1 month], chemotherapy, or anti–tumor 
necrosis factor therapy within the past 3  months) were also 
reported.
 Clinical variables (including presence of fever, vital signs, 
need for intensive support or vasopressors) were assessed 
at the onset of candidemia. The onset of candidemia was de-
fined as the time of the onset of signs of infection (2 or more 
of the following: fever, tachycardia, hypotension, reduced urine 
output, altered mental status, or an increase of SOFA score ≥2 
from baseline). According to Sepsis-3 criteria, the presence of 
septic shock was defined as the requirement of a vasopressor to 
maintain a mean arterial pressure of ≥65 mmHg and a serum 
lactate level >2 mmol/L (>18 mg/dL) in the absence of hypovo-
lemia [12, 13].
Data about the administration of the initial antifungal 
therapy were collected. Initial antifungal therapy defined as 
an antifungal treatment administered within 48 hours of the 
blood culture being taken [14, 15, 17]; the following regimens 
were identified: (i) azole, if the patient received fluconazole 
or voriconazole; (ii) echinocandins, if 1 of the 3 available 
echinocandins (caspofungin, anidulafungin, micafungin) was 
administered; or (iii) amphotericin B. In all the centers involved 
in the study, the choice of antifungal therapy (drug and dosages) 
was driven by an infectious disease consultant.
Data from cases with missing treatment information and 
those who received no antifungal therapy within the first 48 
hours from the blood cultures collection were excluded from 
analysis. Sources of candidemia were defined according to US 
Centers for Disease Control and Prevention definitions [16]. 
Information about device (CVC or PICC) removal was col-
lected. Source control measures were considered within the first 
48 hours of determination of blood culture positivity. These in-
cluded the removal of CVC or surgical or radiologic procedures 
to drain abscesses or fluid collections thought to be the source 
of Candida infection [17]. The outcome variable was mortality 
within 30 days of the onset of candidemia [15].
During the study period, there were no changes in microbio-
logical laboratory techniques in the 5 hospitals. Blood cultures 
were processed using the automated blood culture system 
BacT/Alert 3D (Biomérieux Inc., Marcy l’Etoile, France). 
Confirmation of Candida spp. identification was performed 
by the Vitek-2 system (Biomérieux Inc.). Antifungal suscepti-
bility testing to amphotericin B, echinocandins, and fluconazole 
was performed using the Sensititre YeastOne colorimetric plate 
(TREK Diagnostic Systems, Cleveland, OH). The interpretive 
breakpoints were those proposed in the CLSI (formerly the 
NCCLS) M44-A reference method [18].
This study is reported following the Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) 
recommendations [19].
Study End Point and Statistical Analysis
The aim of the study is to evaluate whether the initial adminis-
tration of echinocandins improved 30-day survival in patients 
affected by candidemia with septic shock compared to those 
without septic shock.
To achieve this goal, a comparison between candidemic 
patients who received echinocandins and patients who received 
azoles within the first 48 hours after the collection of blood 
cultures has been performed in both the groups of patients 
with and without septic shock. Continuous variables were 
compared by the Student t test if normally distributed and the 
Mann-Whitney U test if non-normally distributed. Categorical 
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variables were evaluated using the χ 2 or the 2-tailed Fisher 
exact test. Values for continuous and categorical variables are 
expressed as the mean ±SD or median (interquartile range 
[IQR]) and percentage of the group from which they are de-
rived, respectively.
Separate analyses were performed for the 2 cohorts (septic 
shock vs no septic shock). A  propensity score (PS; the prob-
ability of receiving empirical therapy with echinocandin) was 
calculated for each cohort; all the models obtained for PS 
had an area under the receiver operating characteristic curve 
(AUROC) of ≥0.80. The PS was used in 3 ways: (i) as a covariate 
in multivariate analysis; (ii) to stratify the cohorts according to 
quartiles of the PS; and (iii) to match patients so that each pa-
tient who received empirical treatment with an echinocandin 
was matched with 1 who received treatment with an azole using 
calipers of a width equal to 0.2 of the SD of the logit of the pro-
pensity score. We calculated the variance inflation factor value 
for every variable included to control for the potential occur-
rence of collinearity between the variables included to calcu-
late the PS. Multivariate analyses for mortality at day 30 were 
performed using logistic regression to control for confounding. 
We compared mortality in matched pairs with conditional 
logistic regression. Odds ratios (ORs) or hazard ratios (HRs) 
and 95% confidence intervals (95% CIs) were calculated when 
logistic and Cox regression analysis were used, as appropriate. 
Charlson comorbidity index was used as a dichotomic var-
iable (Charlson >8 and ≤8) according to Classification and 
Regression Tree (CART) analysis.
To control for the site effect, we classified centers into those 
with low (low–mortality risk centers) and high (high–mor-
tality risk centers) mortality using TreeNet considering all 
other variables; therefore, sites classified as high-risk centers 
were those with high mortality after consideration of patients’ 
features.
Statistical signiﬁcance was established at ≤.05. All reported 
P values are 2-tailed. The results obtained were analyzed using 
commercially available statistical software packages (SPSS, ver-
sion 20.0; SPSS, Inc., Chicago, IL; and R, versions 3.0.2 and 
3.5.1; R Development Core Team, Vienna, Austria).
RESULTS
During the study period, a total of 522 episodes of candidemia 
were included in the study. Eighty patients did not receive an 
522 non-ICU patients
with candidemia
80 no antifungal therapy
within 48 hours
3 AMB within 48 hours
172 septic shock 267 non-septic shock
439 treated with antifungal therapy within 48 hours
Hospital 1, N = 120
Hospital 2, N = 33
Hospital 3, N = 78
Hospital 4, N = 75
Hospital 5, N = 133
78 Echinocandins
• Hospital 1, N = 26 (57.8%)
• Hospital 2, N = 6 (54.4%)
• Hospital 3, N = 8 (25.8%)
• Hospital 4, N = 9 (30%)
• Hospital 5, N = 29 (52.7%)
30-day mortality 53.8%
• Hospital 1, N = 13 (50%)
• Hospital 2, N = 4 (66.7%)
• Hospital 3, N = 6 (75%)
• Hospital 4, N = 5 (55.6%)
• Hospital 5, N = 14 (48.3%)
30-day mortality 48.9%
• Hospital 1, N = 9 (47.4%)
• Hospital 2, N = 2 (40%)
• Hospital 3, N = 13 (56.5%)
• Hospital 4, N = 8 (38.1%)
• Hospital 5, N = 14 (53.8%)
30-day mortality 14.3%
• Hospital 1, N = 1 (3.7%)
• Hospital 2, N = 0
• Hospital 3, N = 0
• Hospital 4, N = 5 (35.7%)
• Hospital 5, N = 6 (17.4%)
• Hospital 1, N = 17 (35.4%)
• Hospital 2, N = 4 (26.7%)
• Hospital 3, N = 19 (42.2%)
• Hospital 4, N = 9 (29%)
• Hospital 5, N = 10 (22.7%)
30-day mortality 32.2%
Hospital 1 = Policlinico Umberto I, Rome; Hospital 2 = San Giovanni Addolorata hospital, Rome; Hospital 3 = University Hospital of  Trieste;
Hospital 4 = Azienda Ospedaliera Universitaria Pisana, Pisa; Hospital 5 = University Tor Vergata, Rome.
94 Azoles
• Hospital 1, N = 19 (42.2%)
• Hospital 2, N = 5 (45.5%)
• Hospital 3, N = 23 (74.2%)
• Hospital 4, N = 21 (70%)
• Hospital 5, N = 26 (47.3%)
84 Echinocandins
• Hospital 1, N = 27 (36%)
• Hospital 2, N = 7 (31.8%)
• Hospital 3, N = 2 (4.3%)
• Hospital 4, N = 14 (31.1%)
• Hospital 5, N = 34 (43.6%)
183 Azoles
• Hospital 1, N = 48 (64%)
• Hospital 2, N = 15 (68.2%)
• Hospital 3, N = 45 (95.7%)
• Hospital 4, N = 31 (68.9%)
• Hospital 5, N = 44 (56.4%)
Figure 1. Flowchart of cases of candidemia in non–intensive care unit patients in the 5 study centers. Abbreviations: ICU, intensive care unit.
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antifungal therapy within 48 hours; among these patients, the 
median time from candidemia to death (IQR) was 3 (2–6) 
days. All these patients were excluded from the final analysis 
(Figure 1). Three (0.7%) patients received amphotericin B 
and were excluded from the final analysis. Of the remaining 
439 patients, 162 (36.9%) received an echinocandin and 277 
(63.1%) received azoles within 48 hours of the collection of 
blood cultures (Figure 1).
Of the 439 patients included in the analysis, 172 (39.2%) 
patients had candidemia with septic shock at presentation, 
with a 30-day mortality rate of 51.2%. Among the remaining 
267 patients, the 30-day mortality rate was 26.6%. Table 1 
shows the baseline clinical and demographic characteristics of 
patients by severity group (septic shock vs nonseptic shock). 
The median age (IQR) was similar in patients presenting with 
septic shock at the time of diagnosis of candidemia (79 [71–86] 
years) compared with those without septic shock (76 [67–85] 
years; P =  .059). Candida albicans was the most frequent iso-
late (52.7%), followed by Candida parapsilosis (21.5%), Candida 
tropicalis (9.9%), Candida glabrata (6.8%), Candida krusei 
(2%), and other Candida species (5.6%). In 6 patients (1.4%), 
2 Candida species were isolated. No differences in Candida 
species were observed between the 2 study groups (data not 
shown).
Patients with septic shock were more frequently treated with 
antibiotics in the previous 30 days, were more often hospitalized 
in the previous 3 months, and had more frequently had a PICC 
inserted. Source control was performed more frequently in 
patients with septic shock. With regards to therapy, the ma-
jority of patients without septic shock received azoles as initial 
therapy (68.5%). Conversely, patients with septic shock more 
frequently received an echinocandin as initial therapy (45.3% 
vs 31.5%; P = .003).
Table 2 shows the comparison between candidemic patients 
who received vs did not receive echinocandin therapy ac-
cording to the presence of septic shock. Among nonseptic 
patients, those receiving echinocandins had a lower 30-day 
mortality compared with patients receiving other antifungals 
(14.3% vs 32.2%; P  =  .002), whereas no differences in mor-
tality were observed in patients presenting with septic shock 
(53.8% vs 48.9%; P = .521). High-mortality risk centers were the 
Hospital of Trieste in patients with septic shock and Policlinico 
Umberto I and Hospital of Trieste in those without septic shock 
(Supplementary Figures 1 and 2).
Table 1. Clinical Features and Outcomes of Patients With Candidemia Presenting With and Without Septic Shock
Patients With Candidemia
n = 439
Patients With Septic Shock Patients Without Septic Shock
P Valuen = 172 n = 267
Male 78 (45.3%) 125 (46.8%) .763
Age, median (IQR), y 79 (71–86) 76 (67–85) .059
Diabetes mellitus 79 (45.9%) 130 (48.7%) .572
Chronic renal failure 49 (28.5%) 72 (27%) .728
COPD 53 (30.8%) 78 (29.2%) .721
Solid cancer 41 (23.8%) 55 (20.6%) .423
IBD 4 (2.4%) 11 (4.1%) .323
Previous surgery (30 d) 22 (12.8%) 31 (11.6%) .711
Previous hospitalization (90 d) 65 (37.8%) 66 (24.7%) .003
Previous antibiotic therapy (30 d) 129 (75%) 170 (63.7%) .013
Concomitant antibiotic therapy 89 (51.7%) 182 (68.2%) .001
Immunosuppressive therapy 79 (45.9%) 101 (37.8%) .092
Steroids 62 (36%) 73 (27.3%) .054
CVC 47 (27.3%) 58 (21.7%) .179
PICC 86 (50%) 104 (39%) .023
TPN 118 (68.6%) 134 (50.2%) <.001
Charlson comorbidity index, median (IQR) 7 (6–8) 7 (6–8) .176
Fever 100 (58.1%) 124 (46.4%) .017
Source control 99 (57.6%) 126 (47.2%) .034
Transfer to ICU 12 (7%) 7 (2.6%) .029
Antifungal chemotherapy    
 Echinocandins within the first 48 h 78 (45.3%) 84 (31.5%) .003
 Azole within the first 48 h 94 (54.7%) 183 (68.5%) .003
30-d mortality 88 (51.2%) 71 (26.6%) <.001
Abbreviations: CVC, central venous catheter; ICU, intensive care units; IQR, interquartile range; PICC, peripherally inserted central catheter; TPN, total parenteral nutrition.
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PS analyses in patients with and without septic shock are re-
ported in Supplementary Tables 1 and 2. The PS among patients 
with septic shock showed a P value of .70 for the Hosmer-
Lemeshow goodness-of-fit test and an AUROC of 0.80 (95% CI, 
0.74–0.87), whereas the PS among patients without septic shock 
showed a P value of 0.48 for the Hosmer-Lemeshow goodness-
of-fit test and an AUROC of 0.81 (95% CI, 0.76–0.86).
Univariate analysis of variables associated with 30-day mor-
tality in both cohorts of patients is shown in Supplementary 
Table 3. Multivariate (logistic and Cox regression) analysis of 
mortality at day 30 including the PS as covariates in both study 
groups is shown in Table 3A and B. The PS-adjusted OR of 
echinocandin for 30-day mortality was 0.77 (95% CI, 0.37–1.59; 
P =  .48), and the PS-adjusted HR of echinocandin for 30-day 
mortality was 0.79 (95% CI, 0.37–2.11; P  =  .30). Conversely, 
in patients without septic shock, both logistic and Cox regres-
sion models showed that receiving an echinocandin within the 
first 48 hours was a factor independently associated with lower 
risk of mortality; when potential confounders were added, 
the PS-adjusted OR of echinocandin for 30-day mortality was 
0.40 (95% CI, 0.18–0.88; P = .02) and the PS-adjusted HR was 
0.45 (95% CI, 0.22–0.92; P = .03). However, in a stratified anal-
ysis performed according to the quartiles of the PS (Table 4), 
no significant differences in 30-day mortality rates between 
patients receiving echinocandins or azoles were detected in the 
2 study groups.
Finally, we performed a PS-based matched analysis; we were 
able to match 45 couples to patients with septic shock and 63 
to those without septic shock. The matched patients did not 
show significant differences in exposure to variables related to 
empirical therapy (Supplementary Table 4). Conditional lo-
gistic regression in PS-matched cohorts (Table 5) showed that 
echinocandins within the first 48 hours were associated with 
30-day mortality in patients without septic shock (adjusted HR 
[aHR], 0.43; 95% CI, 0.21–0.91; P = .03), but not in those with 
septic shock (aHR, 0.92; 95% CI, 0.51–1.63; P = .77).
DISCUSSION
This multicenter study suggests that, independent of other 
factors that potentially influence outcome (including early cath-
eter removal), initial echinocandin therapy does not seem to im-
pact the outcome of candidemic patients presenting with septic 
shock. This finding may have significant clinical implications in 
the selection of patients who really benefit from echinocandins 
as initial therapy.
Table 2. Comparison of Candidemic Patients who Received or Not Echinocandins According to the Presence of Septic Shock
Variables 
Patients With Candidemia With Septic  
Shock (n = 172)
Patients With Candidemia Without  
Septic Shock (n = 267)
ECH
n = 78
Azoles 
n = 94  P Value
ECH
n = 84
Azoles
n = 183  P Value
Male 38 (47.8%) 40 (42.6%) .42 37 (44%) 88 (48.1%) .539
Age, median (IQR), y 75 (67–83) 82.5 (72–89) .002 72 (63–80) 78 (70–87) <.001
Diabetes mellitus 42 (53.8%) 37 (39.4%) .058 51 (60.7%) 79 (43.2%) .008
Chronic kidney disease 28 (35.9%) 21 (22.3%) .050 26 (31%) 46 (25.1%) .320
COPD 24 (30.8%) 29 (30.9%) .991 17 (20.2%) 61 (33.3%) .029
Solid cancer 18 (23.1%) 23 (24.5%) .831 10 (11.9%) 45 (24.6%) .017
IBD 2 (2.6%) 2 (2.2%) .848 4 (4.8%) 7 (3.8%) .721
Candida albicans or tropicalis 46 (59%) 62 (66%) .346 55 (65.5) 113 (61.7) .560
Previous surgery (30 d) 11 (14.1%) 11 (11.7%) .639 13 (15.5%) 18 (9.8%) .182
Previous hospitalization (90 d) 28 (35.9%) 37 (39.4%) .641 15 (17.9%) 52 (27.9%) .078
Previous antibiotic therapy (30 d) 64 (82.1%) 65 (69.1%) .052 51 (60.7%) 119 (65%) .496
Immunosuppressive therapy 38 (48.7%) 41 (43.6%) .504 31 (36.9%) 70 (38.3%) .833
Steroids 27 (34.6%) 35 (37.2%) .722 18 (21.4%) 55 (30.1%) .142
Chemotherapy 12 (15.4%) 9 (9.6%) .247 4 (4.8%) 15 (8.2%) .311
CVC 17 (21.8%) 30 (31.9%) .138 11 (13.1%) 47 (25.7%) .021
PICC 32 (41%) 54 (57.4%) .032 33 (39.3%) 71 (38.8%) .939
TPN 49 (62.8%) 69 (73.4%) .137 38 (45.2%) 96 (52.5%) .273
Source control 33 (42.3%) 66 (70.2%) .001 37 (44%) 89 (48.6%) .486
Charlson comorbidity index, median (IQR) 7 (5–8) 7 (6–8) .287 6 (4–8) 7 (6–8) .041
Fever 42 (53.8%) 58 (61.7%) .298 29 (34.5%) 95 (51.9%) .008
Transfer to ICU 5 (6.4%) 7 (7.4%) .791 6 (7.1%) 1 (0.5%) .002
Targeted therapy with echinocandins 69 (88.5%) 14 (14.9%) <.001 74 (88.1%) 11 (6%) <.001
High-risk center 8 (10.3%) 23 (24.5%) .02 29 (34.5%) 93 (50.8%) .01
 30-d mortality 42 (53.8%) 46 (48.9%) .521 12 (14.3%) 59 (32.2%) .002
Abbreviations: CVC, central venous catheter; ECH, echinocandins; ICU,  intensive care units; IQR,  interquartile range; PICC, peripherally inserted central catheter; TPN, total parenteral 
nutrition.
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The efficacy of echinocandins in improving the outcome of 
patients with candidemia is still debated. Current Infectious 
Diseases Society of America guidelines on the management 
of candidemia in non-neutropenic patients recommend the 
use of an echinocandin as initial therapy in unstable patients, 
whereas fluconazole is considered an acceptable alternative in 
selected patients, including those who are not critically ill and 
who are considered unlikely to have a fluconazole-resistant 
Candida species [7]. However, no randomized clinical trials 
have clearly demonstrated the superiority of echinocandins 
compared with a comparator in the treatment of candidemia 
in non-neutropenic adult patients [20–22]. Although Reboli 
Table 3. Logistic Regression (A) and Cox Regression (B) Analysis of 30-Day Mortality Including the Propensity Scores as Covariates in Patients With and 
Without Septic Shock
A  
 Patients With Septic Shocka Patients Without Septic Shockb
OR (95% CI) P OR (95% CI) P
Empirical echinocandins 0.77 (0.37–1.59) .48 0.40 (0.18–0.88) .02
Antibiotic therapy previous 30 d   0.49 (0.27–0.90) .02
Charlson index >8   0.39 (0.17–0.86) .02
Candida albicans or tropicalis   1.77 (0.94–3.34) .07
Chemotherapy   4.48 (1.29–15.60) .02
Chronic renal failure   1.78 (0.91–3.49) 09
Propensity score 0.65 (0.16–2.63) .54 0.18 (0.04–0.88) .04
B   
 Patients With Septic Shock Patients Without Septic Shock
HR (95% CI) P HR (95% CI) P
Empirical echinocandins 0.79 (0.37–2.11) .30 0.45 (0.22–0.92) .03
Antibiotic therapy previous 30 d   0.56 (0.34–0.91) .02
Charlson index >8   0.41 (0.21–0.82) .01
Chemotherapy   1.91 (0.90–4.03) .09
Chronic renal failure   1.89 (1.10–3.23) .02
Propensity score 0.70 (0.26–1.87) .48 0.31 (0.09–1.11) .07
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; IBD, inflammatory bowel disease; ICU, intensive care unit; ROC, receiver operating 
characteristics.
aVariables used for calculating the propensity score in the septic shock cohort: sex, age, hospital, ward of hospitalization, antibiotic therapy in prior 30 days, surgery in prior 30 days, hospi-
talization in prior 90 days, total parenteral nutrition, chronic renal failure, steroids, COPD, chemotherapy, diabetes, solid cancer, IBD, presence at least 2 comorbidities, Charlson >8, source 
control, fever, transfer to ICU. The area under the ROC curve for the propensity score was 0.80.
bVariables used for calculating the propensity score in nonseptic shock cohort: sex, age, hospital, ward of hospitalization, antibiotic therapy in prior 30 days, surgery in prior 30 days, hospi-
talization in prior 90 days, total parenteral nutrition, chronic renal failure, steroids, COPD, chemotherapy, diabetes, solid cancer, IBD, presence at least 2 comorbidities, Charlson >8, fever, 
transfer to ICU. The area under the ROC curve for the propensity score was 0.81.
Table 4. Stratified Analysis of 30-Day Mortality of Patients With or Without Septic Shock Treated With Echinocandins or Azoles Within the First 48 Hours, 
According to Quartiles of the Propensity Score
Propensity Score Quartiles With Septic Shocka
 P
Propensity Score Quartiles Without Septic Shockb
P Propensity Score Range
ECH
n = 78
Azoles
n = 94 Propensity Score Range
ECH
n = 84
Azoles
n = 183
1st (0.03–0.228) 4/6 (66.7) 20/37 (54.0) .564 1st (0.03–0.108) 0/2 (0) 26/65 (40.0) .253
2nd (0.232–0.440) 8/15 (53.3) 12/28 (42.9) .512 2nd (0.110–0.282) 1/15 (6.7) 16/52 (30.8) .059
3rd (0.448–0.652) 12/24 (50.0) 8/19 (42.1) .606 3rd (0.284–0.471) 3/23 (13.8) 11/43 (23.2) .235
4th (0.677–0.964) 18/33 (54.5) 6/10 (60.0) .761 4th (0.475–0.982) 8/44 (18.2) 6/23 (26.1) .450
Total 42/78 (53.8) 46/94 (48.9) .521 Total 12/84 (14.3) 59/183 (32.2) .002
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; IBD, inflammatory bowel disease; ICU, intensive care unit; ROC, receiver operating 
characteristics.
aVariables used for calculating the propensity score in the septic shock cohort: sex, age, hospital, ward of hospitalization, antibiotic therapy in prior 30 days, surgery in prior 30 days, hospi-
talization in prior 90 days, total parenteral nutrition, chronic renal failure, steroids, COPD, chemotherapy, diabetes, solid cancer, IBD, presence at least 2 comorbidities, Charlson >8, source 
control, fever, transfer to ICU. The area under the ROC curve for the propensity score was 0.80.
bVariables used for calculating the propensity score in nonseptic shock cohort: sex, age, hospital, ward of hospitalization, antibiotic therapy in prior 30 days, surgery in prior 30 days, hospi-
talization in prior 90 days, total parenteral nutrition, chronic renal failure, steroids, COPD, chemotherapy, diabetes, solid cancer, IBD, presence at least 2 comorbidities, Charlson >8, fever, 
transfer to ICU. The area under the ROC curve for the propensity score was 0.81.
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/article-abstract/6/7/ofz251/5532720 by guest on 17 July 2019
Antifungal Therapy in Patients With Candidemia • ofid • 7
et  al. [20] demonstrated that the global response at the end 
of treatment was significantly higher in patients treated with 
anidulafungin than in those who received fluconazole, no 
differences in 14- and 28-day mortality between the 2 study 
groups were demonstrated in a secondary post hoc analysis of 
this trial [23]. A prospective study on patients with candidemia 
admitted to IMWs found no differences in mortality rates be-
tween those starting with fluconazole or echinocandin, with 
an unexpected slightly worse survival in those who received 
echinocandins than the other groups [24]. Furthermore, a re-
cent prospective, population-based cohort study on candidemia 
in Spanish hospitals showed that both empirical and targeted 
treatment with fluconazole was not associated with increased 
30-day mortality compared with echinocandins [14].
Our findings suggest that, compared with azole therapy 
(mainly fluconazole therapy), echinocandins are not associated 
with improved mortality in non-ICU patients hospitalized in 
medical wards with septic shock due to candidemia. Several 
reasons may explain these findings. Patients hospitalized in 
IMWs are usually old, with severe rapidly fatal comorbidities, and 
they frequently lack the distinctive signs of systemic infections 
(eg, fever) [25]. This factor might, in part, justify the high mor-
tality recorded in our patients, especially in those without septic 
shock, in whom it is more difficult to detect the presence of an 
infection. Furthermore, among septic patients, echinocandin 
exposure seems to be lower than in healthy volunteers [26–28], 
and patients with severe hypoalbuminemia have lower plasma 
trough levels of echinocandins [29]. Considering the rather fre-
quent occurrence of malnutrition and severe hypoalbuminemia 
in the elderly [30], all these findings justify pharmacokinetic 
studies of the 3 echinocandins in this patient population. 
Finally, we recorded a high mortality rate among patients 
without septic shock receiving fluconazole (32.2%) vs those re-
ceiving echinocandins (14.2%; P = .002). This latter observation 
can be explained in several ways: (i) some relevant confounders 
may not have been measured in the group of patients without 
shock (eg, use of fluconazole in patients with terminal cancer 
was not well assessed by the Charlson comorbidity index); (ii) it 
is not known if azoles were used intravenously in all cases and 
if a loading dose was administered; (iii) data about minimum 
inhibitory concentrations for antifungals were not available for 
all the cases.
Our study has some limitations. The observational nature of 
the study is the major limitation of the study. Furthermore, the 
confidence intervals of the estimation (effect of echinocandin 
therapy in patients with septic shock) are wide, and the power 
to detect a difference can be limited. Moreover, other variables, 
such as prompt fluid resuscitation, use of vasopressors, effica-
cious control of hypoxemia, and serum lactate levels, can in-
fluence the prognosis of patients with septic shock. Thus, in 
this population, it is difficult to identify a unique factor that 
influences mortality. However, our study is consistent with real 
clinical practice and offers an objective evaluation of patients 
with candidemia septic shock hospitalized in IMWs. A strength 
of this study is the large number of patients with candidemia in-
cluded in the analysis, higher than that of other similar cohorts. 
Moreover, we performed a PS-adjusted analysis, considering 
many variables that could potentially influence the outcomes 
of patients. Finally, our study addresses an important ques-
tion that could add important information in the controversy 
about the effect of echinocandins on survival rates. The fact that 
echinocandins do not impact survival rates over fluconazole in 
severely ill patients with candidemia and septic shock implies 
that new diagnostic and treatment strategies are urgently 
needed in this setting.
CONCLUSIONS
In conclusion, we found that in non-ICU septic patients with 
candidemia, echinocandins did not improve 30-day survival 
rates. This finding should not discourage their use in this cate-
gory of patients as recommended, but it could be the basis for 
further studies analyzing the factors influencing the response 
to these drugs. Prevention, early recognition, and management 
of patients at high risk of candidemia before the development 
of septic shock remain the most cost-effective measures to im-
prove the outcome of these patients.
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